SE462781B - Medel mot parkinsonism omfattande l-treo-3,4-dihydroxifenylserin och en dekarboxylas inhibitor - Google Patents
Medel mot parkinsonism omfattande l-treo-3,4-dihydroxifenylserin och en dekarboxylas inhibitorInfo
- Publication number
- SE462781B SE462781B SE8205404A SE8205404A SE462781B SE 462781 B SE462781 B SE 462781B SE 8205404 A SE8205404 A SE 8205404A SE 8205404 A SE8205404 A SE 8205404A SE 462781 B SE462781 B SE 462781B
- Authority
- SE
- Sweden
- Prior art keywords
- dops
- threo
- treo
- administration
- parkinson
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title description 10
- 208000027089 Parkinsonian disease Diseases 0.000 title description 4
- 206010034010 Parkinsonism Diseases 0.000 title description 4
- 239000003112 inhibitor Substances 0.000 title 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 17
- 208000018737 Parkinson disease Diseases 0.000 claims description 14
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims description 12
- 238000007711 solidification Methods 0.000 claims description 12
- 230000008023 solidification Effects 0.000 claims description 12
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 11
- 229960004205 carbidopa Drugs 0.000 claims description 9
- 229960000911 benserazide Drugs 0.000 claims description 5
- 229960001335 benserazide hydrochloride Drugs 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims description 2
- -1 2,3,4-trihydroxyphenyl Chemical group 0.000 claims description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 2
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 150000004682 monohydrates Chemical class 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 17
- QXWYKJLNLSIPIN-JGVFFNPUSA-N droxidopa Chemical compound OC(=O)[C@@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-JGVFFNPUSA-N 0.000 description 17
- 229960002748 norepinephrine Drugs 0.000 description 15
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 14
- 230000006872 improvement Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 description 9
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 8
- 206010044565 Tremor Diseases 0.000 description 8
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229960004502 levodopa Drugs 0.000 description 8
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 229960004479 trihexyphenidyl hydrochloride Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000004031 Carboxy-Lyases Human genes 0.000 description 3
- 108090000489 Carboxy-Lyases Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- AGSIRJFXAANBMW-UHFFFAOYSA-N (1-hydroxynaphthalen-2-yl)iminourea Chemical compound NC(=O)N=NC1=C(O)C2=CC=CC=C2C=C1 AGSIRJFXAANBMW-UHFFFAOYSA-N 0.000 description 1
- QXWYKJLNLSIPIN-JAMMHHFISA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-JAMMHHFISA-N 0.000 description 1
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 229960001280 amantadine hydrochloride Drugs 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 1
- 208000009308 dopamine beta-hydroxylase deficiency Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000032297 kinesis Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- WYDUSKDSKCASEF-UHFFFAOYSA-N procyclidine Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCC1 WYDUSKDSKCASEF-UHFFFAOYSA-N 0.000 description 1
- 229960005360 procyclidine hydrochloride Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56150082A JPS5852219A (ja) | 1981-09-22 | 1981-09-22 | パ−キンソン病治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8205404D0 SE8205404D0 (sv) | 1982-09-21 |
| SE8205404L SE8205404L (sv) | 1983-03-23 |
| SE462781B true SE462781B (sv) | 1990-09-03 |
Family
ID=15489114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8205404A SE462781B (sv) | 1981-09-22 | 1982-09-21 | Medel mot parkinsonism omfattande l-treo-3,4-dihydroxifenylserin och en dekarboxylas inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4497826A (enExample) |
| JP (1) | JPS5852219A (enExample) |
| AU (2) | AU556542B2 (enExample) |
| BE (1) | BE894451A (enExample) |
| CA (1) | CA1184501A (enExample) |
| CH (1) | CH650926A5 (enExample) |
| DE (1) | DE3235093A1 (enExample) |
| FR (1) | FR2513117B1 (enExample) |
| GB (1) | GB2106388B (enExample) |
| IT (1) | IT1212668B (enExample) |
| NL (1) | NL189648C (enExample) |
| NZ (1) | NZ201864A (enExample) |
| SE (1) | SE462781B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6067420A (ja) * | 1983-09-22 | 1985-04-17 | Sumitomo Chem Co Ltd | 精神運動興奮抑制剤 |
| AU575849B2 (en) * | 1983-09-22 | 1988-08-11 | Sumitomo Chemical Company, Limited | Pharmaceutical composition and method for treatment of psychomotor excitement |
| NZ209514A (en) * | 1983-09-22 | 1988-03-30 | Sumitomo Chemical Co | Pharmaceutical compositions containing erythro-3,4-dihydroxyphenylserine and a decarboxylase inhibitor |
| JPS60132935A (ja) * | 1983-12-20 | 1985-07-16 | Sumitomo Chem Co Ltd | フエニルセリン誘導体及びその製造方法 |
| JPS6185318A (ja) * | 1984-10-04 | 1986-04-30 | Sumitomo Seiyaku Kk | 利尿薬 |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4863962A (en) * | 1988-03-02 | 1989-09-05 | Fidia-Georgetown Institute For The Neurosciences | D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease |
| PT99864B (pt) * | 1990-12-21 | 1999-06-30 | Schering Ag | Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato |
| DE4101873C2 (de) | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
| JP3559572B2 (ja) | 1993-01-29 | 2004-09-02 | 住友製薬株式会社 | 急性痛および慢性痛用鎮痛剤 |
| JP3764179B2 (ja) * | 1994-07-05 | 2006-04-05 | 克寛 西野 | 運動・意識または言語障害の機能改善剤 |
| US5668114A (en) * | 1996-05-08 | 1997-09-16 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating hypertension |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
| WO2004100929A1 (en) | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
| US20070010584A1 (en) * | 2003-09-04 | 2007-01-11 | Peroutka Stephen J | Compositions and methods for orthostatic intolerance |
| US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| US7786126B2 (en) * | 2006-06-16 | 2010-08-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising SLV308 and a dopamine agonist |
| ES2571730T3 (es) * | 2006-06-28 | 2016-05-26 | Lundbeck Na Ltd | Composiciones farmacéuticas que comprenden droxidopa |
| AU2008226541B2 (en) * | 2007-03-09 | 2013-05-09 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
| EP2167066B1 (en) * | 2007-05-07 | 2013-06-26 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| JPWO2011001976A1 (ja) | 2009-07-01 | 2012-12-13 | 大日本住友製薬株式会社 | スレオ−３−（３，４−ジヒドロキシフェニル）−ｌ−セリンの製造法 |
| JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL34687A (en) * | 1969-06-18 | 1973-07-30 | Merck & Co Inc | Compounds of a-hydrazino-b-acid (3,4-dihydroxyphenyl) -a-converted propionate |
| US3658968A (en) * | 1970-06-11 | 1972-04-25 | Merck & Co Inc | Composition and method of treatment |
| DE2305209A1 (de) * | 1972-02-14 | 1973-08-23 | Hoffmann La Roche | Pharmazeutisches praeparat |
| AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
| CH580059A5 (enExample) * | 1973-08-22 | 1976-09-30 | Hoffmann La Roche | |
| US3920728A (en) * | 1973-08-22 | 1975-11-18 | Hoffmann La Roche | Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine |
| JPS52125630A (en) * | 1976-04-14 | 1977-10-21 | Kyowa Hakko Kogyo Co Ltd | Antiperkinson drugs containing l-threo-3,4-dihydroxyphenylserine |
| JPS56104815A (en) * | 1980-01-23 | 1981-08-20 | Sumitomo Chem Co Ltd | Remedy for peripheral orthostatic hypotension |
-
1981
- 1981-09-22 JP JP56150082A patent/JPS5852219A/ja active Granted
-
1982
- 1982-09-08 US US06/415,907 patent/US4497826A/en not_active Expired - Lifetime
- 1982-09-09 NZ NZ201864A patent/NZ201864A/en unknown
- 1982-09-13 CA CA000411281A patent/CA1184501A/en not_active Expired
- 1982-09-16 NL NLAANVRAGE8203594,A patent/NL189648C/xx not_active IP Right Cessation
- 1982-09-17 CH CH5515/82A patent/CH650926A5/de not_active IP Right Cessation
- 1982-09-20 FR FR8215806A patent/FR2513117B1/fr not_active Expired
- 1982-09-21 AU AU88578/82A patent/AU556542B2/en not_active Expired
- 1982-09-21 SE SE8205404A patent/SE462781B/sv not_active IP Right Cessation
- 1982-09-21 BE BE0/209060A patent/BE894451A/fr not_active IP Right Cessation
- 1982-09-21 IT IT8268118A patent/IT1212668B/it active
- 1982-09-22 GB GB08227076A patent/GB2106388B/en not_active Expired
- 1982-09-22 DE DE19823235093 patent/DE3235093A1/de active Granted
-
1987
- 1987-01-12 AU AU67501/87A patent/AU575267B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA1184501A (en) | 1985-03-26 |
| IT1212668B (it) | 1989-11-30 |
| JPS5852219A (ja) | 1983-03-28 |
| SE8205404L (sv) | 1983-03-23 |
| SE8205404D0 (sv) | 1982-09-21 |
| NZ201864A (en) | 1985-12-13 |
| US4497826A (en) | 1985-02-05 |
| NL8203594A (nl) | 1983-04-18 |
| FR2513117B1 (fr) | 1986-01-24 |
| DE3235093C2 (enExample) | 1988-12-29 |
| DE3235093A1 (de) | 1983-04-07 |
| JPH0216284B2 (enExample) | 1990-04-16 |
| CH650926A5 (de) | 1985-08-30 |
| GB2106388B (en) | 1986-03-26 |
| AU8857882A (en) | 1983-03-31 |
| NL189648C (nl) | 1993-06-16 |
| FR2513117A1 (fr) | 1983-03-25 |
| NL189648B (nl) | 1993-01-18 |
| AU575267B2 (en) | 1988-07-21 |
| GB2106388A (en) | 1983-04-13 |
| AU6750187A (en) | 1987-04-16 |
| IT8268118A0 (it) | 1982-09-21 |
| BE894451A (fr) | 1983-03-21 |
| AU556542B2 (en) | 1986-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE462781B (sv) | Medel mot parkinsonism omfattande l-treo-3,4-dihydroxifenylserin och en dekarboxylas inhibitor | |
| JP3341898B2 (ja) | Ｎ−プロパルギル−１−アミノインダンのｒ−エナンチオマー、その塩および組成物の使用 | |
| KR100194242B1 (ko) | 눈의 염증성 질환을 치료하기 위한 3-벤조일페닐아세트산 유도체를 함유하는 국소투여가능한 조성물 | |
| McGeer et al. | Administration of dihydroxyphenylalanine to parkinsonian patients | |
| SI9111227B (sl) | Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic | |
| WO2001034594A1 (en) | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors | |
| ES2029769A6 (es) | Procedimiento para preparar medicamentos a base de acidos carboxilicos que contienen azufre como sustancia activa. | |
| EP0228893A3 (en) | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment | |
| AU2002340971B2 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders | |
| Markham et al. | Carbidopa in Parkinson disease and in nausea and vomiting of levodopa | |
| CA1225598A (en) | Pharmaceutical composition and method for treatment of psychomotor excitement | |
| US5330978B1 (en) | Phosphonic acid derivatives and use thereof | |
| AU780328B2 (en) | Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
| KR890003378A (ko) | 혐기성균에 대해 항균작용을 갖는 나프티리딘 화합물 | |
| WO1997002822A1 (en) | Drug for ameliorating brain diseases | |
| RU2155584C2 (ru) | Применение селегилина для лечения эпилептических заболеваний | |
| JP3496114B2 (ja) | 角膜新生血管増殖抑制剤 | |
| WO1998004261A1 (en) | Nefazodone: use in migraine prophylaxis | |
| WO2000002592A1 (en) | Pharmaceutical composition containinig gaba analogs and an antiviral agent to treat shingles | |
| JP3865450B2 (ja) | パーキンソニズム治療剤 | |
| US6410537B1 (en) | Compositions having neuroprotective and analgesic activity | |
| JP2899861B2 (ja) | ショック治療用ピリミドン類及びイミダゾリノン類 | |
| JPH0778022B2 (ja) | 緑内障治療剤 | |
| Sjoerdsma | Some biochemical aspects of treatment and diagnosis of hypertension | |
| MXPA02007747A (es) | Agente para el tratamiento del sindrome de sj°gren. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8205404-0 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8205404-0 Format of ref document f/p: F |